OTCMKTS:PHMMF Pharma Mar Earnings Date & Estimates $77.74 -19.62 (-20.15%) As of 10/28/2026 11:42 AM Eastern Pharma Mar is estimated to report earnings on Thursday, October 29, 2026. Research:ProfileForecast Upcoming Earnings Announcement Announcement DateOctober 29, 2026 Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Pharma MarPharma Mar is expected to post earnings of $0.0038 per share on revenue of $55.60 million.Consensus EstimatesConsensus EPS$0.0038Expected Revenue$55.60 millionPrepare for the Earnings CallCompany Profile Pharma Mar Earnings FAQ When does Pharma Mar report earnings? Pharma Mar (OTCMKTS:PHMMF) is estimated to report earnings on Thursday, October 29, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What is the consensus EPS estimate for Pharma Mar? Analysts expect Pharma Mar to post earnings of $0.0038 per share for the quarter. How much revenue is Pharma Mar expected to report? The consensus revenue estimate for Pharma Mar is $55.60 million for the quarter. Pharma Mar Earnings HeadlinesPharma Mar (PHMMF) Projected to Release Earnings on ThursdayOctober 22, 2026 | americanbankingnews.comPharma Mar Continues September Share Buyback on Madrid ExchangeOctober 2, 2026 | tipranks.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 29 at 1:00 AM | Stansberry Research (Ad)Pharma Mar Wins U.K. Approval for Zepzelca Combo in Small-Cell Lung CancerSeptember 25, 2026 | tipranks.comPharma Mar: Expensive Multiples For Zepzelca's GrowthSeptember 7, 2026 | seekingalpha.comPharma Mar Details August Share Buyback Transactions on Madrid BourseSeptember 3, 2026 | tipranks.comSee More Pharma Mar Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharma Mar? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharma Mar and other key companies, straight to your email. Email Address About Pharma MarPharma Mar (OTCMKTS:PHMMF), S.A. is a Spanish biopharmaceutical company focused on discovering, developing and commercializing innovative medicines derived from marine organisms. The company specializes primarily in oncology and maintains a research platform dedicated to identifying novel compounds with potential anticancer activity. Its principal products include Yondelis (trabectedin), an anticancer treatment used in certain cases of advanced soft-tissue sarcoma and ovarian cancer, and Zepzelca (lurbinectedin), a therapy developed for patients with metastatic small-cell lung cancer whose disease has progressed during or after platinum-based chemotherapy. Pharma Mar also continues to advance additional marine-derived compounds through clinical development and research programs. Founded in Spain in 1986, Pharma Mar serves international markets through its own commercial operations in selected European countries and through licensing, distribution and development partnerships in other regions, including the United States. The company is headquartered in the Madrid area and was established by José María Fernández Sousa-Faro, who has served as a longstanding senior executive and chairman.View Pharma Mar ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure WinnerThe Invisible AI Backbone: Corning's AI Fiber PlayWhy Tesla’s Upside Is About More Than a SpaceX MergerBoeing Got Its MAX 10 Approval, But Q3 Delivered a Reality CheckPalantir's Q3 Bar Is Higher Than It Looks: 3 Numbers to WatchAmkor's Mobile Business Is Slowing, But Its AI Ambitions Aren'tSherwin-Williams Remains Evergreen in a Frozen Housing Market Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
